Poster Session 2-16 Indolent Lymphoma: Treatment (2)

[PS2-16-3] Refractory mantle cell lymphoma successfully treated with switching therapy from VR-CAP to ibrutinib

Shohei Udagawa¹, Yasuo Aota^1,2, Tadahiro Honda², Yuko Okuda³, Akihiko Gotoh^1,2,4 (1.Department of Internal Medicine, Kohsei Chuo General Hospital, Tokyo, Japan, 2.Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan, 3.Tokyo-Kita Medical Center Hematology, Tokyo, Japan, 4.Department of Hematology. Tokyo Medical University, Tokyo, Japan)